OrbiMed Closes $1.9B Life Sciences Fund in $3B Double Close

OrbiMed has raised a $1.9 billion life sciences fund as part of a double close totaling roughly $3 billion, according to Dealroom.

The figure makes this one of the largest private capital raises for healthcare and biotech investing announced this cycle. A double close — wrapping two vehicles in a single fundraising event — signals that OrbiMed's limited partners committed to both funds simultaneously rather than staggering their pledges.

What did OrbiMed actually raise?

The headline number is $1.9 billion earmarked specifically for life sciences. The combined close, per Dealroom's report, brings the total across the effort to about $3 billion, meaning a second vehicle accounts for the remaining roughly $1.1 billion. Dealroom's report did not break out the name, size or mandate of that companion fund.

The takeaway in plain terms: OrbiMed convinced investors to write two sets of checks at once, and the life sciences piece alone approaches $2 billion.

Why a $3B close matters now

Life sciences fundraising has cooled from its pandemic-era peak, when biotech valuations and public-market exits pulled record sums into the sector. A close of this size, reported by Dealroom, suggests institutional appetite for healthcare-focused strategies has not disappeared — it has consolidated around established managers with long track records.

OrbiMed is one of the few firms whose entire franchise sits in healthcare, spanning venture investing in drug developers and medical technology as well as public equities and credit. That breadth is part of why a double close of this scale is feasible: limited partners can allocate across risk profiles inside one manager's platform.

The takeaway: in a harder fundraising market, the money is concentrating with specialists who already have the scale.

What comes next

Deploying nearly $2 billion into life sciences means OrbiMed will be writing first checks into new biotech startups, funding later-stage clinical companies, or both — the report did not specify the deployment split. For founders and research institutions hunting capital, a fresh pool of this size at a sector-dedicated firm is a concrete signal that drug-development and medtech financing remains open for business, even where generalist investors have pulled back.